Daxor Leverages MedAxiom CV Transforum Spring’26 to Accelerate Commercial Adoption of Blood Volume Analysis
Rhea-AI Summary
Daxor (Nasdaq: DXR) will exhibit its Blood Volume Analyzer (BVA™) at the MedAxiom CV Transforum Spring’26, April 30–May 2, 2026, at Sawgrass Marriott, Ponte Vedra Beach, FL. The company says the forum supports its commercial strategy to engage cardiovascular decision-makers and accelerate BVA adoption to inform value-based care.
According to the company, peer-reviewed studies link BVA-guided care to large outcome differences: 30‑day mortality down 82%, 1‑year mortality down 86%, 30‑day readmissions down 56%, and 55% shorter length of stay when done on admission (P<0.001).
Positive
- None.
Negative
- None.
News Market Reaction – DXR
On the day this news was published, DXR gained 5.39%, reflecting a notable positive market reaction. Argus tracked a peak move of +5.8% during that session. Argus tracked a trough of -17.0% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $4M to the company's valuation, bringing the market cap to $71.74M at that time. Trading volume was above average at 1.6x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner shows 4 peers split between gains and losses (2 up, 2 down), with names like STXS and ZJYL moving up and MLSS and NEPH down, suggesting mixed but sector-wide activity alongside DXR’s move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 08 | New BVA program | Positive | +2.3% | Launch of new BVA program at a high-volume Ohio cardiology center. |
| Mar 26 | Clinical data update | Positive | -2.9% | Clinical data showing BVA better detects capillary leak than common indices. |
| Mar 17 | Conference showcase | Positive | +0.2% | Showcase of next-gen portable BVA and outcome data at ACC.26. |
| Mar 10 | Product debut | Positive | +1.6% | Debut of rapid, portable blood volume analyzer at SCCM 2026. |
| Mar 09 | Investor conference | Neutral | -0.7% | CEO participation and meetings at iAccess Alpha Best Ideas conference. |
Recent news and clinical updates have generally seen modest positive price reactions, with one notable divergence on favorable clinical data.
Over the past two months, Daxor has steadily highlighted commercial and clinical momentum. In March–April 2026, it announced new BVA program adoption in Ohio, showcased its next‑generation portable analyzer at ACC.26, and debuted the device at SCCM 2026. Clinical data from SCCM 2026 validated BVA’s mechanistic specificity versus traditional indices. Investor‑facing participation in the iAccess conference complemented these efforts. Today’s MedAxiom conference news continues this pattern of combining clinical outcomes data with targeted commercialization and outreach.
Market Pulse Summary
The stock moved +5.4% in the session following this news. A strong positive reaction aligns with Daxor’s pattern of modest gains on commercial and conference-related news, as seen after prior BVA program and product announcements. The article reiterates peer-reviewed data showing up to 82% and 86% mortality reductions and significant readmission and length-of-stay benefits, which support the strategic push at MedAxiom. Investors must weigh this against ongoing operating losses of $268,598 in 2025 and recent equity financing.
Key Terms
p<0.001 medical
AI-generated analysis. Not financial advice.
Oak Ridge, TN, April 28, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will exhibit its Blood Volume Analyzer (BVA™) technology at the MedAxiom CV Transforum Spring’26 Conference. The event, being held at the Sawgrass Marriott Golf Resort & Spa, Ponte Vedra Beach, FL, from April 30 – May 2, 2026, is a premier venue for cardiovascular thought leaders and industry innovators to drive the future of cardiac care delivery.
The CV Transforum serves as a strategic touchpoint for Daxor to engage with high-level decision-makers and cardiovascular service line leaders. As hospitals increasingly shift toward value-based reimbursement models, Daxor’s BVA technology provides a clear economic and clinical value proposition.
“Our continued participation in the MedAxiom forum is a key component of our commercial strategy,” said Michael Feldschuh, CEO and President of Daxor. “By engaging directly with MedAxiom members, we are accelerating the adoption of our BVA technology. We believe this focus on high-impact clinical partnerships is essential for scaling our commercial footprint and reshaping how providers manage complex cardiovascular patients.”
BVA guided care has been shown in peer-reviewed studies to significantly improve multiple measures of patient outcomes including a reduction in 30-day mortality by
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR) is tackling healthcare's "multi-billion-dollar silent crisis", the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor is proud to manufacture and distribute its patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic which offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Daxor is ISO certified and operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility, positioning the company for accelerated market expansion.
For more information, please visit our website at Daxor.com.
Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact
Bret Shapiro
COO – Head of Capital Markets
COREIR
516-222-2560
brets@coreir.com|www.coreir.com
